ScholarLens Back to search
2008•Journal of the International AIDS SocietyOpen access

Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine

Silvia Nozza, Francesca Visco, Albane Soria, Laura Galli, Stefania Salpietro, Nicola Gianotti, Elisabetta Carini, Alba Bigoloni, Giuliana Fusetti, Giuseppe Tambussi, Adriano Lazzarin, Antonella Castagna

Open full text 10 citations

Abstract

Purpose of the studyWith the availability of new drug classes, the full suppression is a realistic goal even for heavily pre-treated patients.We prospectively evaluated the magnitude of CD4 recovery (CR) in this setting.from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK.

Open-access reader

About this research paper

What this paper is about

Purpose of the studyWith the availability of new drug classes, the full suppression is a realistic goal even for heavily pre-treated patients.We prospectively evaluated the magnitude of CD4 recovery (CR) in this setting.from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Purpose of the studyWith the availability of new drug classes, the full suppression is a realistic goal even for heavily pre-treated patients.We prospectively evaluated the magnitude of CD4 recovery (CR) in this setting.from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK.

Key concepts: Maraviroc, Raltegravir, Etravirine, Medicine, Regimen, Darunavir, CCR5 receptor antagonist, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine — Research Paper | ScholarLens